{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:06:28Z","timestamp":1789059988744,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejca.2026.116992","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:44:59Z","timestamp":1787067899000},"page":"116992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Expression patterns of potential targets for antibody-directed therapy in metastatic castration-resistant prostate cancer patients"],"prefix":"10.1016","volume":"246","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2594-2227","authenticated-orcid":false,"given":"Tanja C.","family":"van Dijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0605-1901","authenticated-orcid":false,"given":"Marcel","family":"Smid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2490-9991","authenticated-orcid":false,"given":"Debbie G.J.","family":"Robbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khrystany T.","family":"Isebia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.M.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5462-9486","authenticated-orcid":false,"given":"Nick","family":"Beije","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116992_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/bco2.116","article-title":"Mortality in men with castration-resistant prostate cancer-a long-term follow-up of a population-based real-world cohort","volume":"3","author":"Khoshkar","year":"2022","journal-title":"BJUI Compass"},{"key":"10.1016\/j.ejca.2026.116992_bib2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41391-023-00725-8","article-title":"Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer (mCRPC) in the US medicare population","volume":"27","author":"Freedland","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ejca.2026.116992_bib3","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/s41391-021-00344-1","article-title":"The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population","volume":"24","author":"Westgeest","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ejca.2026.116992_bib4","article-title":"Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making","volume":"2017","author":"Abida","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2026.116992_bib5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","article-title":"Genomic and phenotypic heterogeneity in prostate cancer","volume":"18","author":"Haffner","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ejca.2026.116992_bib6","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41585-025-01014-w","article-title":"Targeting the tumour cell surface in advanced prostate cancer","volume":"22","author":"Boixareu","year":"2025","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ejca.2026.116992_bib7","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116992_bib9","unstructured":"ClinicalTrials.gov - NIH National Library of Medicine (US). Identifier NCT07164443. A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) (KLK2-comPAS). 2025-12-19 ed."},{"key":"10.1016\/j.ejca.2026.116992_bib10","unstructured":"ClinicalTrials.gov - NIH National Library of Medicine (US). Identifier NCT06691984. Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute). 2026-01-22 ed."},{"key":"10.1016\/j.ejca.2026.116992_bib11","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116992_bib12","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer","volume":"42","author":"Klumper","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116992_bib13","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ajur.2021.05.001","article-title":"Molecular markers of systemic therapy response in urothelial carcinoma","volume":"8","author":"Claps","year":"2021","journal-title":"Asian J Urol"},{"key":"10.1016\/j.ejca.2026.116992_bib15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","article-title":"Pan-cancer whole-genome analyses of metastatic solid tumours","volume":"575","author":"Priestley","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2026.116992_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ejca.2026.116992_bib17","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/bioinformatics\/btv098","article-title":"Sambamba: fast processing of NGS alignment formats","volume":"31","author":"Tarasov","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ejca.2026.116992_bib18","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ejca.2026.116992_bib19","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12859-018-2246-7","article-title":"Gene length corrected trimmed mean of M-values (GeTMM) processing of RNA-seq data performs similarly in intersample analyses while improving intrasample comparisons","volume":"19","author":"Smid","year":"2018","journal-title":"BMC Bioinforma"},{"key":"10.1016\/j.ejca.2026.116992_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113379","article-title":"Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response","volume":"195","author":"Bosi","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116992_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20133291","article-title":"EDB-FN targeted peptide-drug conjugates for use against prostate cancer","volume":"20","author":"Park","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejca.2026.116992_bib22","first-page":"11","article-title":"762 A first-in-human phase 1 clinical study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the EDB+FN targeting ADC PYX-201 in participants with advanced solid tumors","author":"Wilks","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116992_bib24","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1038\/s41467-019-13084-7","article-title":"The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact","volume":"10","author":"van Dessel","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2026.116992_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe1505","article-title":"Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets","volume":"376","author":"Tang","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ejca.2026.116992_bib26","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2026.116992_bib27","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1126\/science.abn0478","article-title":"Lineage plasticity in prostate cancer depends on JAK\/STAT inflammatory signaling","volume":"377","author":"Chan","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ejca.2026.116992_bib28","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","article-title":"Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer","volume":"76","author":"Paschalis","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2026.116992_bib29","first-page":"1932","article-title":"Outcomes for patients with metastatic castration-resistant prostate cancer and liver metastasis receiving [(177)Lu]Lu-PSMA-617","volume":"65","author":"Muniz","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejca.2026.116992_bib30","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000502845","article-title":"HER2 regulates cancer stem cell activities via the Wnt signaling pathway in gastric cancer cells","volume":"97","author":"Jung","year":"2019","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2026.116992_bib31","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2023.5483","article-title":"FUT2 promotes the tumorigenicity and metastasis of colorectal cancer cells via the Wnt\/beta\u2011catenin pathway","volume":"62","author":"Liu","year":"2023","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ejca.2026.116992_bib32","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO-24-01989","article-title":"Phase I, first-in-human study of FOR46 (FG-3246), an immune-modulating antibody-drug conjugate targeting CD46, in patients with metastatic castration-resistant prostate cancer","volume":"43","author":"Aggarwal","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116992_bib33","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121497","article-title":"Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer","volume":"3","author":"Su","year":"2018","journal-title":"JCI Insight"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:09:10Z","timestamp":1789056550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926007732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":30,"alternative-id":["S0959804926007732"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116992","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression patterns of potential targets for antibody-directed therapy in metastatic castration-resistant prostate cancer patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116992","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116992"}}